Dermatology
| Psoriasis
Dermatology
Psoriasis
Zasocitinib (TAK-279), an oral, allosteric, highly selective TYK2 inhibitor, reduced PASI body region and individual component scores in a phase 2b trial in moderate-to-severe plaque psoriasis
book_2
Source:
EADV Congress 2025
calendar_today
Published on Medfyle:
October 2025
import_contacts
3
min
In this medfyle
This post hoc analysis compared PASI body region and component scores for patients receiving zasocitinib versus placebo – findings consistent improvements. This investigational agent could represent a future treatment option.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2025 Infomedica-Medfyle. All rights reserved.
Source: Zasocitinib (TAK-279), an oral, allosteric, highly selective TYK2 inhibitor, reduced PASI body region and individual component scores in a phase 2b trial in moderate-to-severe plaque psoriasis. Bhutani-Jacques T, et al. Presented at EADV 2025; abstract 3813.
The information and data provided is for information purposes only. The author(s) of the original presentation had no involvement in the creation of this content.
